Musi wa19 Chivabvu 2022, China's National Medical Products Administration (NMPA) yakabvumidza chikumbiro chekushambadzira cheBayer's.Vericiguat(2.5 mg, 5 mg, uye 10 mg) pasi pezita rechiratidzo Verquvo™.

Mushonga uyu unoshandiswa muvarwere vakuru vane zviratidzo zvisingaperi zvemoyo kusakundikana uye kuderedzwa kwejection chikamu (chikamu chejection <45%) avo vanogadziriswa mushure mechiitiko chechangobva kuitika chekugadzirisa nemishonga inopinza, kuderedza dambudziko rekuiswa muchipatara nokuda kwekukundikana kwemoyo kana emergency intravenous diuretic therapy.

Mvumo yeVericiguat yakabva pamigumisiro yakanaka kubva kuVICTORIA yekudzidza, iyo yakaratidza kuti Vericiguat inogona kuwedzera kuderedza ngozi yakakwana yekufa kwemoyo uye kuchipatara nokuda kwekukundikana kwemoyo ne4. kukundikana vaive nechiitiko chechangobva kuitika chekutadza kwemoyo uye vaive vakagadzikana pakurapa intravenous nechikamu chakaderedzwa ejection. (chikamu che ejection <45%).

Muna Ndira 2021, Vericiguat yakabvumidzwa muUnited States kurapwa kwechiratidzo chisingaperi chekutadza kwemoyo muvarwere vane ejection chikamu chiri pasi pe45% mushure mekusangana nechiitiko chekutadza kwemoyo.

Muna Nyamavhuvhu 2021, chikumbiro chitsva chemushonga cheVericiguat chakagamuchirwa neCDE uye chakazoverengerwa mukuongorora kwekutanga uye kubvumidzwa nechikonzero che "mishonga yekukurumidzira yekiriniki, madhiragi matsva nemishonga mitsva yakavandudzwa yekudzivirira nekurapa hosha huru dzinotapukira uye. zvirwere zvisingawanzo ”.

Muna Kubvumbi 2022, iyo 2022 AHA/ACC/HFSA Nhungamiro yeManagement of Heart Failure, iyo yakapihwa pamwe chete neAmerican College of Cardiology (ACC), American Heart Association (AHA), uye Heart Failure Society of America (HFSA). ), yakagadziridza pharmacologic kurapwa kwemoyo kusakundikana neyakaderedzwa ejection chikamu (HFrEF) uye yakabatanidza Vericiguat mumishonga inoshandiswa kurapa varwere vane njodzi huru. HFrEF uye kutadza kwemoyo kuwedzeredza kunoenderana neyakajairwa kurapwa.

Vericiguatis sGC (soluble guanylate cyclase) inosimudzira ine novel mechanism yakabatanidzwa yakagadziridzwa neBayer naMerck Sharp & Dohme (MSD). Inogona kupindira zvakananga mu cell-signaling mechanism disorder uye kugadzirisa NO-sGC-cGMP nzira.

Zvidzidzo zvepreclinical uye zvekiriniki zvakaratidza kuti NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) nzira yekuratidzira ndiyo inogona kutariswa yekusingaperi kukundikana kwemoyo kufambira mberi uye kutadza kwemoyo. Pasi pemamiriro ehupenyu, iyi nzira yekusaina ndiyo nzira yakakosha yekudzora myocardial mechanics, cardiac function, uye vascular endothelial function.

Pasi pemamiriro epathophysiological ekushaya simba kwemoyo, kuwedzera kuzvimba uye kusagadzikana kwevascular kunoderedza NO bioavailability uye kudzika cGMP synthesis. Kushaikwa kwecGMP kunotungamirira ku dysregulation yevascular tension, vascular and cardiac sclerosis, fibrosis uye hypertrophy, uye coronary uye renal microcirculatory dysfunction, nokudaro kunowedzera kuenderera mberi kwekukuvara kwemyocardial, kuwedzera kuzvimba uye kuwedzera kuderera kwemwoyo uye renal basa.